Kimberly Park, Vice President Sales and Marketing, PriCara, Ortho-McNeil Janssen Pharmaceuticals
S
Kimberly Park
Vice President Sales and Marketing PriCara, Ortho-McNeil Janssen Pharmaceuticals
TRACK RECORD: Led Merck's managed care group and HIV/AIDS franchise
STARTED OUT: In SmithKline Beckman's management training program
We all have our moments. For Kimberly Park, her moment came when she decided to stay in her high-ranking job—and take on the additional task of being a mother. At first, she says, she wasn't confident that she would be able to manage her priorities. "But I soon realized that I could contribute at the same level—maybe even a higher level—because I became more focused. It was a chance for me to say, 'I'm not perfect, but I can do both.'" Now, Park co-chairs the Women's Leadership Initiative at J&J, where she heads up the company's primary care group. As for the affinity group, Park is proud to note that it's earned it stripes—and it's working. Meanwhile, women in other pharmas have taken a cue, and have set up similar groups at their own companies.
Kimberly Park
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Talphera Cuts NEPHRO CRRT Study Size, Secures $14.8 Million Private Placement
April 1st 2025The trial size adjustment, along with protocol modifications and the addition of higher-enrollment sites, is expected to facilitate completion of the NEPHRO CRRT study of Niyad in patients undergoing renal replacement therapy by the end of 2025.
